SSIs are not designed for incremental improvements to the ‘standard of treatment’ – they are designed to re-invent, complement, and replace the standard.
Dr. Simon Sutcliffe, Chief Medical Officer, Qu Biologics
Supported by a committed group of investors.
Qu Biologics is a private, clinical-stage biotechnology company. Qu Biologics has raised USD$39M in equity funding from high net worth, family offices, and angel investors, and an additional USD$12M in non-dilutive funding.
Rather than blocking or stimulating a single receptor or pathway, SSI treatments are designed to restore the full depth and breadth of the body's normal immune response in a targeted organ. We believe this new approach has the potential to revolutionize the way cancer and chronic inflammatory diseases are treated and prevented. We are passionate and innovative and committed to achieve this goal and the full potential of SSIs.
Qu Biologics is raising a Series B USD$25M equity round to expand our team and clinical development program to include a randomized double-blind placebo-controlled study in pancreatic cancer in addition to our current two enrolling studies. Please join us in transforming Medicine.
If you are interested in investment opportunities and learning more about our novel treatment approach and the innovative team behind it, please enter your contact information here, contact Chief Business Officer Andrew Rae at firstname.lastname@example.org, or click on one of the three links, below, for additional information.